Abstract 4112
Background
Cisplatin, a common chemotherapeutic for metastatic breast cancer (MBC), is recommended to be applied at 75 mg/m2 every 3 weeks, but divided doses over several days are commonly used. Toxicity profile difference of these 2 dosing regimens is rarely reported, so we retrospectively compared toxicity of cisplatin at 75mg/m2 one day versus 25mg/m2 for 3 consecutive days repeated every three weeks focusing on nausea/vomiting, abnormalities of serum electrolytes and renal function.
Methods
Between December 2008 and May 2015, 227 patients underwent 1 day of cisplatin treatment with hydration and magnesium supplementation and 256 patients underwent 3 days of treatment without hydration and magnesium supplementation were retrospectively analyzed. The number of patients with first-line and second-line chemotherapy in 1 day plan group was 99 and 109, and in 3 days plan group was 128 and 147.
Results
The objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were similar between the two groups. Grade 1–4 nausea/vomiting differed significantly between the 1-day and 3-day regimen (161[70.9%] vs. 132[51.6%], p < 0.001), but with no difference in grade 3 or 4 toxicity. 1-day cisplatin treatment led to more significant magnesium loss (44.4% vs. 28.3%, p = 0.025) and no difference for other serum electrolyte level changes. Serum creatinine level higher than upper normal limit was observed less in one-day arm (9.4% vs. 15.0%, p = 0.062) with marginal difference, indicating possibly less renal toxicity. There were no treatment-related deaths.
Conclusions
In conclusion, toxicity profile of two dosing regimen of cisplatin is different. When cisplatin is given clinically at 75 mg/m2 once every three weeks, more attention should be paid to controlling nausea/vomiting better and strengthening the supplementation of magnesium.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor
Presenter: Zhao Sun
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
2124 - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features
Presenter: Hanyue Xu
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract